Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep;10(9):3669–3683. doi: 10.21037/tau-21-777

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Translational Andrology and Urology. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

MiR-124 contributed to cisplatin resistance in renal cell carcinoma (RCC) cells. (A) 786-O cells were treated with 10 µM cisplatin for 0, 12, 24, and 36 h. The filtered miRNA array data were used for hierarchical clustering analysis. (B) The level of miR-124 was detected by real-time polymerase chain reaction (PCR). (C) The overexpression level of miR-124 in Caki-1 cells was measured by quantitative real-time PCR (qPCR). Cell viability and half maximal inhibitory concentration (IC50) value of Caki-1 cells to cisplatin were evaluated using the Cell Counting Kit-8 (CCK-8) assay. (D) The overexpression level of miR-124 in 786-O cells was measured by qPCR. Cell viability and IC50 value of 786-O cells to cisplatin were evaluated using the CCK-8 assay. *, P<0.05; **, P<0.01; and ***, P<0.001.